SEC Filings

Show all

Stock Information

: (Common Stock)

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Corporate Governance

The Board of Directors of Selecta Biosciences sets high standards for the company’s employees, officers, and directors.
Implicit in this philosophy is the importance of sound corporate governance.

Events
Featured Reports
Mar 12, 2020
2019 Annual Report
May 02, 2019
2019 Proxy Statement

Press Releases

05 Apr
Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference
WATERTOWN, Mass. , April 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief
11 Mar
Selecta Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
-   First-in-human dose-escalation study to evaluate ability of ImmTOR™  to mitigate immunogenicity of AAV capsid initiated with initial data expected in the fourth quarter of 2021 - -   Methylmalonic acidemia   (MMA) gene therapy program in collaboration with AskBio expected to enter the clinic in
04 Mar
Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights
WATERTOWN, Mass. , March 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that that it plans to
01 Mar
Selecta Biosciences to Participate in the H.C. Wainwright Global Life Sciences Conference
WATERTOWN, Mass. , March 01, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief
Stock Information
Stock Information
Information Request
Information Request
Financial Information
Financial Information
FAQ
FAQ